Tocagen Logo Green

No One Should Die of CancerTM

Our lead cancer-selective immunotherapy product is under investigation in a Phase 3 clinical trial, Toca 5, for patients with brain cancer.

Tocagen believes the immune system can be safely activated to fight the patient’s cancer. Driven by this vision, we are developing first-in-class, broadly applicable, product candidates designed to activate a patient’s immune system against their own cancer from within.